Recently, two agents targeting the Fibroblast Growth Factor Receptor (FGFR) family genes—pemigatinib and infigratinib—have been approved by Health Canada for previously treated, unresectable, or metastatic CCA with FGFR2 gene rearrangements. The gene discussed is FGFR2; the disease is cholangiocarcinoma.